Clinical trials: Central Obesity
Metabolism and Nutrition Disorder, Obesity
Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors
This trial is conducted in Europe. The aim of this trial is to investigate bioequivalence between single-dose liraglutide administered subcutaneously with two different pen-injectors.
- Trial name
- NCT02207348
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Obesity
A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.
The purpose of this study is to determine whether GSK1521498 will cause weight loss in obese but otherwise healthy subjects with over-eating behaviours.
- Trial name
- NCT01195792
- Testing
- GSK1521498
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
22q11 Deletion Syndrome, DiGeorge Syndrome
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and…
- Conditions
- 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18
- Trial name
- SMART (NCT02381457)
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 20,960 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Obesity
A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.
- Trial name
- FGFR4-CS2 (NCT02476019)
- Testing
- ISIS-FGFR4RX
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
- Trial name
- NCT02717858
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Obesity, Weight Loss
ReShape Vest™ for the Treatment of Obesity (Europe)
To assess the safety and effectiveness of the LGV in treating obese subjects with a BMI of 35 kg/m2 to 55 kg/m2 who have failed one or more conservative weight-reduction alternative(s), such as supervised diet, exercise, and…
- Trial name
- NCT03918564
- Testing
- Laparoscopic Gastric Vest (LGV)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- ReShape Lifesciences
Obesity
Effect of Tesofensine on Energy Balance in Humans.
Purpose: To evaluate the effect of tesofensine on energy balance
- Trial name
- NCT00428415
- Testing
- Tesofensine
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroSearch A/S
Obesity &Amp; Overweight
Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus
- Trial name
- NCT07192263
- Testing
- IN-B00009
- Volunteers
- 300 people
- Sponsor
- HK inno.N Corporation
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Obesity
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)
The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks.
- Trial name
- NCT00434096
- Testing
- rimonabant (SR141716)
- Where
- Japan
- Volunteers
- 915 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in…
- Trial name
- NCT00042601
- Testing
- Pramlintide acetate
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Adolescent Obesity, Obesity in Adolescence
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in…
- Conditions
- Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
- Trial name
- NCT03922945
- Testing
- VI-0521 oral capsule, Lifestyle Modification
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- VIVUS LLC